RM2, there was an article in the Globe back in Dec 2018 about the shift in BP's packaging up their OTC products and spinning them off because of low margins caused by the degree of competition. The article indicated these BPs including Pfizer were looking to build there high value drug lines via acquisition of small biotechs that show promise. The time could not be more ripe for RVX and ZE for some sort of deal.

I think one of the challanges is that these companies have many projects in the works and they are caught in "their own momentum behind projects they have invested in". It is very difficult to change their thinking to a new path, a new theory unless there is a break through.

So, will the zen3694 x mCRPC trial be considered worthy of shifting some BP's investments toward. Pfizer has shown interest ( a major achievement for ZE) with the joint trial of zen3694 on TNBC, but not enough interest for a CVR type deal.

So far there seems to be an attitude of "show us more proof"!

GLTA

Toinv